rivaroxaban and Immunoglobulin-Light-chain-Amyloidosis

rivaroxaban has been researched along with Immunoglobulin-Light-chain-Amyloidosis* in 1 studies

1 other study(ies) available for rivaroxaban and Immunoglobulin-Light-chain-Amyloidosis

Article	Year
Liver injury during rivaroxaban treatment in a patient with AL amyloidosis. European journal of clinical pharmacology, 2021, Volume: 77, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Factor Xa Inhibitors; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Pulmonary Embolism; Rivaroxaban	2021